A GHK-Cu dosage number needs its original setting.
A number looks wonderfully definite. It can still be the wrong number for the question. GHK-Cu has no FDA-approved drug label with a standard human schedule, and this page doesn’t supply one.

Concentration
How much is in a given volume.
In the Lee hair study, researchers tested topical blends at 50 mg/mL and 100 mg/mL. Those were concentrations of a complex containing GHK and 5-aminolevulinic acid. They weren’t strengths of GHK-Cu alone, and they weren’t injection doses.
The six-month study involved 45 men with male-pattern hair loss. Hair counts rose more with the blends than with the comparison lotion. That result belongs to those mixtures and that setting. Changing the ingredient, the reason for use or the route takes you beyond what this experiment tested.
A concentration describes what’s in a mixture. It doesn’t, by itself, tell you how much reaches a person or what amount would suit them.
Delivery
What actually gets where it needs to go?
A review of topical GHK explains the difficulty of getting it through the skin’s outer barrier. A product’s formula matters to that problem. Two products can name the same ingredient without showing that they deliver it in the same way.
The skin-sample experiment measured copper passing through and remaining in pieces of human skin. It didn’t measure an absorbed dose of intact GHK-Cu in a living person. There’s no reliable calculation here that turns that lab result into a personal injection schedule.
The useful question is whether the evidence fits the actual product. Copying a research number while changing the preparation doesn’t recreate the study.
Prescription
A personal decision still needs a clinician.
You may also see the rat study of GHK breakdown used to explain how often someone might inject. The study tested free GHK in rats. It didn’t establish how GHK-Cu behaves over time inside people, so it can’t supply a human schedule.
A clinical conversation can cover the intended goal, the evidence for it, the proposed route and what follow-up would mean. It can also cover what would lead to changing the plan. These are questions for a licensed clinician who can review the person, rather than a routine copied from a discussion thread.
FDA’s concerns about injectable GHK-Cu remain relevant when a prescription is discussed. Access to care and evidence of benefit are separate questions. The safety page explains what is known and what remains open.